Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TAHIRA P ALVES

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1003913617
CMS profile
477686
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,141.00

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,107.22 104
Education $33.78 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TAHIRA P ALVES

NPI 1003913617 · CMS profile ID 477686

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003913617?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TAHIRA P ALVES, NPI 1003913617, CMS profile ID 477686. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003913617?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TAHIRA P ALVES, NPI 1003913617, CMS profile ID 477686. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003913617?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TAHIRA P ALVES, NPI 1003913617, CMS profile ID 477686, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1003913617?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $2,141.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–106 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $19.0701/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110542267 CMS
GlaxoSmithKline, LLC. $16.7401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115898826 CMS
Amgen Inc. $17.8601/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115422897 CMS
Novartis Pharmaceuticals Corporation $24.8901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086754237 CMS
Aurinia Pharma U.S., Inc. $26.9301/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150675412 CMS
AstraZeneca Pharmaceuticals LP $22.7601/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110541989 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $355.37 21
PY2020 $564.85 30
PY2021 $788.37 49
PY2022 $1,756.97 89
PY2023 $1,845.76 87
PY2024 $2,141.00 106
PY2025 $7,629.96 113

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,248,393.83 233
PY2024 Principal investigator $2,005,103.87 41
PY2023 Principal investigator $252,846.48 8
PY2022 Principal investigator $282,869.63 10
PY2021 Principal investigator $290,904.26 3
PY2020 Principal investigator $6,480.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

233 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $155.69 12/30/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678042
Principal investigator 1 CSL Behring $20,146.00 12/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678260
Principal investigator 1 CSL Behring $164.00 12/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678286
Principal investigator 1 CSL Behring $75.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678608
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678610
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678612
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678614
Principal investigator 1 CSL Behring $164.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678616
Principal investigator 1 CSL Behring $169.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678618
Principal investigator 1 CSL Behring $169.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678620
Principal investigator 1 CSL Behring $204.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678622
Principal investigator 1 CSL Behring $204.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678624
Principal investigator 1 CSL Behring $338.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678626
Principal investigator 1 CSL Behring $338.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678628
Principal investigator 1 CSL Behring $615.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678630
Principal investigator 1 CSL Behring $710.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678632
Principal investigator 1 CSL Behring $710.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678634
Principal investigator 1 CSL Behring $1,230.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678636
Principal investigator 1 CSL Behring $2,435.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678638
Principal investigator 1 CSL Behring $2,460.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678640
Principal investigator 1 CSL Behring $225.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678694
Principal investigator 1 CSL Behring $1,088.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678696
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841647
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841649
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841789
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841791
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841793
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841795
Principal investigator 1 AKEBIA THERAPEUTICS INC $723.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841797
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841799
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841801
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841803
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841805
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841807
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841809
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841811
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841813
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841815
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841817
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841819
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841821
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842077
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842273
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842275
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842277
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842279
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842281
Principal investigator 1 AKEBIA THERAPEUTICS INC $228.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842283
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842285
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842287
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842289
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842291
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842293
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842295
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842297
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842299
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842301
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842303
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842305
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842307
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842309
Principal investigator 1 AKEBIA THERAPEUTICS INC $228.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842311
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842313
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842315
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842317
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842431
Principal investigator 1 CSL Behring $3,893.00 11/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679040
Principal investigator 1 CSL Behring $175.12 11/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678030
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841591
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841593
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841643
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841645
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842049
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842051
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842053
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842075
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842548
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842764
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842780
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842806
Principal investigator 1 AKEBIA THERAPEUTICS INC $729.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842812
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842818
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842848
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842938
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843046
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843048
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843050
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843052
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843190
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843192
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843194
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843196
Principal investigator 1 AKEBIA THERAPEUTICS INC $164.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845376
Principal investigator 1 AKEBIA THERAPEUTICS INC $40.00 11/05/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845426
Principal investigator 1 CSL Behring $37,902.00 10/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678924
Principal investigator 1 CSL Behring $8,140.00 10/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678901
Principal investigator 1 CSL Behring $144.95 10/08/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678240
Principal investigator 1 CSL Behring $338.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679154
Principal investigator 1 CSL Behring $974.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679156
Principal investigator 1 CSL Behring $75.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679198
Principal investigator 1 CSL Behring $7,916.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679200
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841469
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841471
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841473
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841475
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841477
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841479
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841481
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841483
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841485
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841487
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841489
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841491
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841923
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841925
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841927
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841929
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841931
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841933
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841935
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841937
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841939
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841941
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841943
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841945
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842445
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842465
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842481
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842499
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842503
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842529
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842533
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842541
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842544
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842562
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842582
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842630
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842642
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842656
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842670
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842674
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842678
Principal investigator 1 AKEBIA THERAPEUTICS INC $213.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842684
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842688
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842690
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842712
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842714
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842718
Principal investigator 1 AKEBIA THERAPEUTICS INC $265.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842730
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843342
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843344
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843346
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843348
Principal investigator 1 AKEBIA THERAPEUTICS INC $943.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845253
Principal investigator 1 AKEBIA THERAPEUTICS INC $230.00 10/03/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845313
Principal investigator 1 CSL Behring $507.00 10/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679124
Principal investigator 1 CSL Behring $204.00 10/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679176
Principal investigator 1 CSL Behring $204.00 10/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679178
Principal investigator 1 CSL Behring $213.49 09/26/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678192
Principal investigator 1 CSL Behring $27,311.00 09/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679086
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 09/10/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843478
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 09/10/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843480
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 09/10/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843482
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 09/10/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843484
Principal investigator 1 CSL Behring $82.00 09/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673710
Principal investigator 1 CSL Behring $225.00 09/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673712
Principal investigator 1 CSL Behring $612.00 09/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673714
Principal investigator 1 CSL Behring $612.00 09/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679206
Principal investigator 1 CSL Behring $224.83 09/08/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678184
Principal investigator 1 CSL Behring $27,416.00 08/20/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673634
Principal investigator 1 CSL Behring $204.00 08/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673722
Principal investigator 1 CSL Behring $204.00 08/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673934
Principal investigator 1 CSL Behring $974.00 08/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673936
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843622
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843624
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843626
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843628
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843886
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843890
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843893
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843896
Principal investigator 1 AKEBIA THERAPEUTICS INC $164.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845027
Principal investigator 1 AKEBIA THERAPEUTICS INC $40.00 08/06/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845085
Principal investigator 1 CSL Behring $16.71 08/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678200
Principal investigator 1 CSL Behring $354.75 08/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678162
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844402
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844406
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844411
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844415
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844419
Principal investigator 1 AKEBIA THERAPEUTICS INC $759.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844422
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,362.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844427
Principal investigator 1 AKEBIA THERAPEUTICS INC $912.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844430
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,480.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844434
Principal investigator 1 AKEBIA THERAPEUTICS INC $360.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844438
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,767.00 07/23/2025 Non-covered Recipient Entity
San Antonio Kidney
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844442
Principal investigator 1 CSL Behring $70,117.00 07/16/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673906
Principal investigator 1 CSL Behring $92.24 07/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678134
Principal investigator 1 CSL Behring $15,070.00 06/30/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673846
Principal investigator 2 CSL Behring $34,791.00 06/30/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673980
Principal investigator 1 CSL Behring $764.43 06/30/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678116
Principal investigator 1 CSL Behring $494,776.50 06/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673978
Principal investigator 1 CSL Behring $116.40 06/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678112
Principal investigator 1 CSL Behring $194.61 06/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678100
Principal investigator 1 CSL Behring $456,262.00 05/28/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673974
Principal investigator 1 CSL Behring $12,123.00 05/14/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673818
Principal investigator 1 CSL Behring $432.43 05/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678076
Principal investigator 3 CSL Behring $441,162.00 04/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673786
Principal investigator 1 CSL Behring $2,126.00 04/25/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673940
Principal investigator 1 CSL Behring $30.30 04/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678068
Principal investigator 1 CSL Behring $3,628.00 04/16/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674156
Principal investigator 1 CSL Behring $1,045.72 04/14/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678056
Principal investigator 1 CSL Behring $16.71 04/11/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678050
Principal investigator 1 CSL Behring $16.71 04/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678044
Principal investigator 1 CSL Behring $665.92 04/08/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678428
Principal investigator 2 CSL Behring $128,298.00 04/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673992
Principal investigator 2 CSL Behring $3,016.78 04/01/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673994
Principal investigator 1 CSL Behring $6,165.00 03/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674126
Principal investigator 3 CSL Behring $430,840.00 03/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673990
Principal investigator 1 CSL Behring $724.78 02/27/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678372
Principal investigator 1 CSL Behring $612.18 02/21/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678360
Principal investigator 2 CSL Behring $375,603.00 02/20/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673988
Principal investigator 1 CSL Behring $15,484.00 02/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674098
Principal investigator 1 CSL Behring $907.47 02/14/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678346
Principal investigator 1 CSL Behring $497.29 02/04/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678324
Principal investigator 1 CSL Behring $624.82 01/24/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678320
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,240.00 01/22/2025 Non-covered Recipient Entity
SAN ANTONIO KIDNEY DISEASE CENTER PHYSICIANS GROUP
Cardiovascular Renal and Metabolism Lokelma Hyperkalemia No dispute reported 06/30/2026 1185550625
Principal investigator 2 CSL Behring $245,027.00 01/20/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673986
Principal investigator 1 CSL Behring $507.00 01/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674068
Principal investigator 1 CSL Behring $150.00 01/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674170
Principal investigator 1 CSL Behring $4,219.00 01/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674048
Principal investigator 1 CSL Behring $18,257.00 01/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674050
Principal investigator 2 CSL Behring $233,917.00 01/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674186